| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Rockwell Medical, Inc.$5.61
-0.15 (-2.69%)
C 58Pipeline Score MedTech · Commercial
Market Cap
31.30 M
EPS
-0.15
P/E Ratio
-
Value Trade
397.96 K
SEC Financials
Q1 2026Dilution Risk
Revenue
17.34 M
Operating CF
-167.00 K
Total Assets
57.42 M
Total Liabilities
21.57 M
Equity
35.86 M
D/E Ratio
12,345
-0.43 %
Week
-8.69 %
1 Month
-21.48 %
3 Month
-10.24 %
6 Month
-91.99 %
5 Year
-98.67 %
All Time
Cash Data
Cash Position
23.89 M
Monthly Burn
56.00 K
Runway
424.4 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
16.80 K
52 Week Range
0.74 - 2.10
% held by Insiders
11.63 %
% held by Institutions
10.08 %
Enterprise Value
21.80 M
Total Shares
39.40 M
Short %
2.36 %
Float Shares
34.08 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Rockwell Medical, Inc.
588Total events
0Upcoming
126Tier-1 (high impact)
2007 – 2026Coverage
Event history 588
Mar 26, 2026
Jan 20, 2026
▲Quarterly UpdateCorporate
Preliminary unaudited Q4 and full-year 2025 financial results reported
Jan 5, 2026
▲Partnership / LicenseCorporate
Amended and Restated Product Purchase Agreement extended through December 31, 2026 with one of the largest US dialysis providers
hemodialysissource ↗
Mar 2024
◆Quarterly UpdateCorporate
Full-year 2023 financial results expected to be reported in March 2024
Jan 8, 2024
▲Debt Royalty FinancingCorporate
Amended loan and security agreement with Innovatus, extending maturity to Jan 2029 and reducing interest rate
Jan 8, 2024
2024
◆Quarterly UpdateCorporate
2024 guidance: net sales $84-88M, gross profit $12-14M, adjusted EBITDA $0-0.5M
Drug Pipeline Intelligence
C58
Pipeline Score $470M
Pipeline ValueValuation Signal
4
Drugs Scored15.0x
rNPV / MCap Top 84%
Micro Cap (rank 147 of 912)
Percentile RankRockwell Medical, Inc. carries a moderate pipeline score (58/100), with $12.0B risk-adjusted pipeline value, led by SFP in End Stage Renal Disease (Phase 3), across $148B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SFP Small molecule | End Stage Renal Disease | Phase 3 | NCT01503021 | 49% | $8.5B | COMPLETED | 718 | - | - | Jan 1, 2014 | - | Oct 25, 2016 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Ferric Pyrophosphate Citrate | Hemodialysis Dependent Chronic Kidney Disease | — | 2021-11-16 | mean anti-Xa activity, activated prothrombin time (aPTT), Thrombin time (TT) concentrations were comparable across all timepoints at baseline, and throughout the study; more than 1.6mm million doses have been safely administered Read More | Rockwell Medical Study Demonstrates No Drug-drug Interaction Between Ferric Pyrophosphate Citrate and Unfractionated Heparin Read More | |
Ferric Pyrophosphate Citrate | Hemodialysis Dependent Chronic Kidney Disease | — | 2021-11-16 | mean anti-Xa activity, activated prothrombin time (aPTT), Thrombin time (TT) concentrations were comparable across all timepoints at baseline, and throughout the study; more than 1.6mm million doses have been safely administered Read More | Rockwell Medical Study Demonstrates No Drug-drug Interaction Between Ferric Pyrophosphate Citrate and Unfractionated Heparin Read More | |
Ferric Pyrophosphate Citrate | Hemodialysis Dependent Chronic Kidney Disease | — | 2021-11-16 | mean anti-Xa activity, activated prothrombin time (aPTT), Thrombin time (TT) concentrations were comparable across all timepoints at baseline, and throughout the study; more than 1.6mm million doses have been safely administered Read More | Rockwell Medical Study Demonstrates No Drug-drug Interaction Between Ferric Pyrophosphate Citrate and Unfractionated Heparin Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RMTI
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RMTI Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-11-20 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RMTI▼ -9.8%on this news
Rockwell Medical Announces 1-for-10 Reverse Stock Split
Rockwell Medical has announced a 1-for-10 reverse stock split. This decision is part of the company's strategy to improve its stock price and meet listing requirements. The reverse split will reduce the number of shares outstanding while increasing the share price proportionately.
Read more →RMTIRockwell Medical to Release Fourth Quarter and Full-Year 2025 Results on Thursday, March 26, 2026
Rockwell Medical, Inc. will announce its financial and operational results for Q4 and the full year of 2025 on March 26, 2026. The announcement will include a press release at 6:00am ET and a live webcast at 8:00am ET. The company emphasizes its commitment to providing high-quality hemodialysis products and exceptional customer service.
Read more →RMTI▼ -6.4%on this news
Rockwell Medical Named 'Great Place to Work' for Fourth Year in a Row
Rockwell Medical has been certified as a Great Place to Work for the fourth consecutive year. This recognition highlights the company's commitment to fostering a supportive and empowering workplace culture. The Vice President of Human Resources emphasized the importance of their dedicated employees in driving the company's mission and values. Rockwell Medical continues to focus on innovation and delivering quality products to dialysis providers.
Read more →RMTI▲ +31.6%on this news
Rockwell Medical Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Financial Results
Rockwell Medical, Inc. reported preliminary unaudited financial results for Q4 and full-year 2025, highlighting a significant revenue increase and positive cash flow. The company achieved an Adjusted EBITDA positive status and improved its gross margin to 22%. Looking ahead, Rockwell aims to focus on revenue growth, profitability, and diversification of its product portfolio.
Read more →RMTI▲ +14.4%on this news
Rockwell Medical Extends Product Purchase Agreement Through 2026 With One of the Largest Dialysis Providers in the United States
Rockwell Medical has extended its product purchase agreement with a major U.S. dialysis provider through December 31, 2026. The amended agreement includes increased pricing for products, highlighting the importance of Rockwell's reliable supply chain and high-quality offerings. The company's leadership expresses optimism about strengthening the partnership further.
Read more →RMTI▼ -7.1%on this news
Rockwell Medical Announces First Quarter 2025 Results Reports net sales of $18.9 million for the first quarter of 2025, a 17% decrease from net sales of $22.7 million for the first quarter of 2024. Reports gross profit o
Rockwell Medical, Inc. reported its financial and operational results for the first quarter of 2025, highlighting a 17% decrease in net sales to $18.9 million compared to $22.7 million in the same period of 2024. The company recorded an operating loss of $1.360 million, slightly higher than the $1.324 million loss in Q1 2024. Despite the decrease in sales and losses, Rockwell Medical remains committed to business growth and diversification, maintaining its 2025 annual guidance for net sales and gross margin.
Read more →RMTI▼ -20.5%on this news· ran to -32% by day 3
Rockwell Medical Announces Fourth Quarter and Full-Year 2024 Financial and Operational Results Achieves profitability on an adjusted EBITDA basis for the full-year 2024, the first time in the Company's history. Reports r
Rockwell Medical, Inc. announced its financial results for the fourth quarter and full year of 2024, highlighting its first-ever adjusted EBITDA profitability. The company achieved net sales exceeding $100 million and improved gross margins. Looking ahead, Rockwell expects 2025 to be a transitional year, indicating potential challenges in maintaining current sales levels due to changes in its customer base. The company remains focused on sustaining profitability and optimizing its operations.
Read more →RMTI▼ -7.9%on this news
Rockwell Medical Achieves Profitability on an Adjusted EBITDA Basis in the Fourth Quarter 2023 and Record Net Sales, Gross Profit and Gross Margin for the Full-Year 2023 Reports record net sales for second year in a row,
Rockwell Medical announced significant financial results for the fourth quarter and full year of 2023, achieving profitability on an adjusted EBITDA basis for the first time in its history. The company reported record net sales of $84 million to $88 million for 2024, alongside an increase in gross profit. Mark Strobeck, CEO, noted improvements in financial health and operational efficiencies, which they expect to sustain and build upon in the coming years. Rockwell Medical is focused on enhancing its product offerings and expanding its market presence domestically and internationally.
Read more →RMTI▼ -5.7%on this news
Rockwell Medical Amends Loan and Security Agreement with Innovatus Life Sciences Lending Fund Defers principal payments of $8.0 million up to three years, reduces Rockwell's need for additional operating capital, and enh
Rockwell Medical, Inc. has amended its loan agreement with Innovatus Life Sciences Lending Fund, deferring $8 million in principal payments for up to three years and reducing its interest rate. The company expects to achieve better financial flexibility and enhance its cash balance as it moves towards profitability. Additionally, preliminary projections for Q4 2023 indicate a significant increase in net sales compared to the previous year. However, Rockwell is still forecasting net losses for both the fourth quarter and the full year.
Read more →RMTIRockwell Medical Announces Third Quarter 2023 Results Net sales for the third quarter of 2023 were $23.8 million, including concentrates product sales of $21.6 million, both of which were the highest sales generated to-d
Rockwell Medical, Inc. announced its financial results for the third quarter of 2023, reporting net sales of $23.8 million, the highest in its history. This achievement marks a significant increase from the previous year, driven by strategic enhancements in its business model and substantial growth in its hemodialysis concentrates segment. The company anticipates continued growth, projecting net sales to be between $82.0 million and $86.0 million for 2023, alongside expected gross profit increases. Despite reporting a net loss, Rockwell Medical is on target for profitability in the fourth quarter of 2023.
Read more →RMTIDocument Rockwell Medical Announces Second Quarter 2023 Results Net sales for the six months ended
Rockwell Medical reported its second quarter earnings for 2023, showing an 8% increase in net sales to $37.7 million and a significant rise in gross profit by 260% to $3.6 million. Following its acquisition of Evoqua's hemodialysis concentrates business, the company has raised its 2023 net sales guidance, now anticipating between $82 million and $86 million. Rockwell Medical plans to achieve profitability by the fourth quarter of 2023, positioning itself for stronger growth in the future. However, it also noted a continued net loss, which was down compared to the previous year, but slightly increased quarter-over-quarter.
Read more →RMTI▼ -7.4%on this news· ran to -48% by day 3
Rockwell Medical Acquires Hemodialysis Concentrates Business from Evoqua Water Technologies Adds profitable business that generates approximately $18 million in annual revenue and will add over $3.3 million in annual EBI
Rockwell Medical, Inc. has acquired the hemodialysis concentrates business from Evoqua Water Technologies for $11 million plus milestone payments. This acquisition is projected to generate approximately $18 million in annual revenue and an additional $3.3 million in EBITDA. The deal expands Rockwell's market presence and customer base, enabling it to become a leading supplier of hemodialysis products in the United States. The firm has adjusted its revenue guidance for 2023 to reflect this impactful acquisition.
Read more →RMTIRockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer
Rockwell Medical, Inc. Appoints Mark Strobeck, Ph.D., as President and Chief Executive Officer WIXOM, Mich., June 22, 2022 -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management, t
Read more →RMTIRockwell Medical, Inc. Transforming Iron Deficiency Therapy (NASDAQ: RMTI) Corporate Presentation June 2022 Forward - Looking Statements Certain statements in this presentation may constitute "forward - looking statement
Rockwell Medical, Inc. Transforming Iron Deficiency Therapy (NASDAQ: RMTI) Corporate Presentation June 2022 Forward - Looking Statements Certain statements in this presentation may constitute "forward - looking statements" within the meaning of federal securities laws, including
Read more →RMTI▼ -6.2%on this news· ran to -17% by day 3
Rockwell Medical, Inc. Transforming Iron Deficiency Therapy (NASDAQ: RMTI) Corporate Presentation May 2022 Forward - Looking Statements Certain statements in this presentation may constitute "forward - looking statements
Rockwell Medical, Inc. Transforming Iron Deficiency Therapy (NASDAQ: RMTI) Corporate Presentation May 2022 Forward - Looking Statements Certain statements in this presentation may constitute "forward - looking statements" within the meaning of federal securities laws, including,
Read more →RMTI▲ +8.6%on this news
Rockwell Medical Announces Upcoming Poster Presentation at the National Home Infusion Association’s 2022 Annual Conference
Rockwell Medical, Inc. announced a poster presentation at the NHIA 2022 Annual Conference, scheduled for March 12-16 in Nashville, Tennessee. The presentation will focus on the management of iron deficiency anemia in home parenteral nutrition patients. Timothy T. Chole will present the findings, highlighting challenges and opportunities for improvement in this area.
Read more →RMTIRockwell Medical, Inc. to Present at Aegis Virtual Conference
WIXOM, Mich., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the
Read more →RMTIRockwell Medical Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Rockwell Medical, Inc. announced an Inducement Grant for a new employee to purchase 10,000 shares of common stock at an exercise price of $0.40. This grant, approved by the independent directors, is part of the company's strategy to attract talent under Nasdaq Listing Rule 5635(c)(4). The shares will vest over three years, contingent on continued employment.
Read more →RMTI▼ -8.6%on this news· ran to -23% by day 1
Rockwell Medical Announces Regulatory Approval of Triferic® Dialysate in South Korea
Rockwell Medical announced that its partner, Jeil Pharmaceutical, has received regulatory approval for Triferic Dialysate in South Korea. This product is designed to maintain hemoglobin levels in adult patients with hemodialysis-dependent chronic kidney disease. The approval offers nephrologists an additional treatment option, potentially improving patient care and reducing nursing workload.
Read more →RMTI▲ +17.4%on this news
Rockwell Medical Announces Regulatory Approval of Triferic® AVNU in South Korea
Rockwell Medical has announced that its partner, Jeil Pharmaceutical, received regulatory approval for Triferic AVNU in South Korea. This approval allows for the commercialization of the product, which is expected to launch in June/July 2022. Triferic AVNU is designed for iron supplementation in hemodialysis patients, addressing a critical need in this patient population.
Read more →RMTIRockwell Medical, Inc. to Present at H.C. Wainwright BioConnect 2022 Conference
Rockwell Medical, Inc. will present at the H.C. Wainwright BioConnect 2022 Conference. The presentation will be available for on-demand listening starting January 10, 2022. Rockwell Medical is known for its innovative treatments for iron deficiency and has two FDA-approved therapies for hemodialysis patients. The company aims to expand its technology platform for broader applications.
Read more →RMTICorporate Presentation January 2022 www.RockwellMed.com ROCKWELL MEDICAL, INC. TRANSFORMING IRON DEFICIENCY AND ANEMIA MANAGEMENT (NASDAQ: RMTI) FORWARD - LOOKING STATEMENTS 2 Certain statements in this presentation may
Corporate Presentation January 2022 www.RockwellMed.com ROCKWELL MEDICAL, INC. TRANSFORMING IRON DEFICIENCY AND ANEMIA MANAGEMENT (NASDAQ: RMTI) FORWARD - LOOKING STATEMENTS 2 Certain statements in this presentation may constitute "forward - looking statements" within the meanin
Read more →RMTI▼ -8.6%on this news
Rockwell Medical Receives Important Feedback from FDA on its IND Application for Phase 2 Trial of Ferric Pyrophosphate Citrate in Home Infusion
Rockwell Medical has received feedback from the FDA on its IND application for a Phase 2 trial of Ferric Pyrophosphate Citrate (FPC) aimed at treating iron deficiency anemia in home infusion settings. The FDA has requested additional data related to microbiology and stability to support the proposed drug administration method. Rockwell Medical is optimistic about addressing these requests and believes this therapy could significantly benefit patients by allowing them to avoid clinic visits.
Read more →RMTI▲ +13.5%on this news
Rockwell Medical Study Demonstrates No Drug-drug Interaction Between Ferric Pyrophosphate Citrate and Unfractionated Heparin
Rockwell Medical announced positive results from a study published in the Journal of Bioequivalence & Bioavailability, showing no clinically relevant drug-drug interaction between Ferric Pyrophosphate Citrate (FPC) and unfractionated heparin (UFH). The study confirms previous findings and supports the safe co-administration of these treatments in hemodialysis patients. FPC is FDA-approved for maintaining hemoglobin in patients with hemodialysis-dependent chronic kidney disease.
Read more →RMTI▼ -5.4%on this newsshared move
Rockwell Medical, Inc. Provides Third Quarter 2021 Financial and Operational Update
Rockwell Medical, Inc. reported a strong third quarter for 2021, with net sales reaching $16.0 million, reflecting growth from previous quarters. The company submitted an Investigational New Drug application for Ferric Pyrophosphate Citrate (FPC) to treat iron deficiency anemia in patients receiving home infusion. Additionally, positive results from a pilot study on Triferic were presented at ASN Kidney Week 2021, demonstrating effective maintenance of hemoglobin in chronic hemodialysis patients.
Read more →RMTIRockwell Medical Submits Investigational New Drug Application with FDA for its Proposed Clinical Trial of FPC as a Treatment for Iron Deficiency Anemia in Patients Receiving Home Infusion
WIXOM, Mich., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it has su
Read more →RMTIRockwell Medical, Inc. to Report Third Quarter 2021 Financial and Operating Results on November 15, 2021
WIXOM, Mich., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will h
Read more →RMTIRockwell Medical Presents Triferic Real World Evidence Update at ASN Kidney Week 2021
-Results from pilot observational analysis demonstrate maintenance of hemoglobin and reduction of total IV iron requirement in adult patients on Triferic receiving chronic hemodialysis- -Findings align with pivotal trials of Triferic and prior Real World Evidence- WIXOM, Mich.,
Read more →RMTIRockwell Medical, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
WIXOM, Mich., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that members
Read more →RMTIRockwell Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
WIXOM, Mich., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the
Read more →RMTI▼ -6.4%on this newsshared move
Rockwell Medical, Inc. Provides Second Quarter 2021 Financial and Operational Update
-Entered into exclusive license agreement with Drogsan Pharmaceuticals for the rights to commercialize Triferic® in Turkey- -Extended multi-year distribution agreement with Nipro Medical for dialysis concentrates in LATAM and the Caribbean- -Q2 2021 conference call and webcast
Read more →RMTIRockwell Medical, Inc. to Report Second Quarter 2021 Financial and Operating Results on August 16, 2021
WIXOM, Mich., July 29, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will h
Read more →RMTIRockwell Medical, Inc. Files Pre-IND Meeting Request with FDA for its Proposed Clinical Trial of FPC as a Treatment for Iron Deficiency Anemia in Patients Receiving Home Infusion
WIXOM, Mich., June 28, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it has su
Read more →RMTIRockwell Medical Announces Extension of Multi-Year Distribution Agreement with Nipro Medical Corporation for Dialysis Concentrates
WIXOM, Mich., June 11, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it extend
Read more →RMTIRockwell Medical and Drogsan Pharmaceuticals Enter into Exclusive License Agreement for the Rights to Commercialize Triferic in Turkey
WIXOM, Mich. and ANKARA, Turkey, June 08, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, and Drogsan
Read more →RMTIRockwell Medical, Inc. to Present at the 2021 LD Micro Invitational XI
WIXOM, Mich., June 03, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that members o
Read more →RMTIRockwell Medical, Inc. Provides First Quarter 2021 Financial and Operational Update
-Home Infusion FPC Program expected to initiate Phase 2 trial in second half of 2021- -Company received marketing approval in Canada for Triferic AVNU™- -Conference call and webcast on Monday, May 17th at 4:30 p.m. ET- WIXOM, Mich., May 17, 2021 (GLOBE NEWSWIRE) -- Rockwell Me
Read more →RMTIRockwell Medical, Inc. to Report First Quarter 2021 Financial and Operating Results on May 17, 2021
WIXOM, Mich., May 03, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will ho
Read more →RMTIRockwell Medical Announces Marketing Approval of Triferic AVNU™ in Canada
WIXOM, Mich., April 27, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that Triferic
Read more →RMTIRockwell Medical Presents Data on Diagnosis and Management of Iron Deficiency Anemia in Home Parenteral Nutrition Patients at the NHIA 2021 Annual Conference
WIXOM, Mich., April 22, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it prese
Read more →RMTIRockwell Medical, Inc. Provides Fourth Quarter and Full Year 2020 Financial and Operational Update
- 2020 revenue of $62.2 million - - Ended the year with $58.7 million in cash, cash equivalents and investments - - Conference call and webcast on Wednesday, March 31st at 4:30 p.m. ET - WIXOM, Mich., March 31, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a
Read more →RMTIRockwell Medical, Inc. to Report Fourth Quarter and Full Year 2020 Financial and Operating Results on March 31, 2021
WIXOM, Mich., March 18, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will
Read more →RMTIRockwell Medical, Inc. to Present at the H.C. Wainwright Global Life Sciences Conference
WIXOM, Mich., March 04, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that members
Read more →RMTIRockwell Medical Announces U.S. Availability of Triferic AVNU for Replacement of Iron and Maintenance of Hemoglobin in Patients on Hemodialysis
WIXOM, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that Triferic
Read more →RMTIRockwell Medical Announces Submission of Triferic New Drug Application in South Korea by Partner, Jeil Pharmaceutical Co., Ltd.
WIXOM, Mich., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management, today announced that its partner in South Korea, Jeil Pharmaceutica
Read more →RMTIRockwell Medical Announces Dosing of First Patient in Pivotal Triferic Phase 3 Trial by Partner, Wanbang Biopharmaceuticals, in China
WIXOM, Mich., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for patients around the world, today announce
Read more →RMTIRockwell Medical, Inc. to Present at H.C. Wainwright BioConnect 2021 Conference
WIXOM, Mich., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for pat
Read more →RMTIRockwell Medical, Inc. Provides Third Quarter 2020 Financial and Operational Update
-Ended the quarter with $67.3 million in cash, cash equivalents and investments- -Q3 2020 revenue of $15.3 million- -U.S. commercial launch of Triferic® AVNU expected in Q1 2021- -Poised to enroll first patient in Phase 3 clinical trial of Triferic in China- -Unveiled plans t
Read more →RMTIRockwell Medical to Report Third Quarter 2020 Financial and Operating Results on November 9, 2020
WIXOM, Mich., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management and improving outcomes for pat
Read more →RMTIRockwell Medical, Inc. Announces Presentations at the American Society of Nephrology Virtual Kidney Week 2020
WIXOM, Mich., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the
Read more →RMTIRockwell Medical Announces Growth Plan and New Therapeutic Opportunities for Its Ferric Pyrophosphate Citrate (FPC) Platform
-New indications for FPC platform provide significant growth opportunity- -Anticipates Type C meeting with FDA for home infusion in Q1 2021 and for acute heart failure in 2H 2021- -Well capitalized to fund dialysis business and advance clinical development for home infusion ind
Read more →RMTIRockwell Medical Announces $35.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
WIXOM, Mich., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around th
Read more →RMTIRockwell Medical Announces Appointment of Russell L.
Rockwell Medical Announces Appointment of Russell L. Skibsted as Executive Vice President, Chief Financial Officer and Chief Business Officer WIXOM, Mich., September 15, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq RMTI) ("Rockwell Medical" or the "Company"), a biopha
Read more →RMTIRockwell Medical Announces Appointment of Russell L. Skibsted as Executive Vice President, Chief Financial Officer and Chief Business Officer
WIXOM, Mich., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around th
Read more →RMTIRockwell Medical Enters into Exclusive License Agreement with Jeil Pharmaceutical Co., Ltd., for the Rights to Commercialize Triferic in South Korea
WIXOM, Mich., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around th
Read more →RMTIRockwell Medical to Host Conference Call and Webcast with Management and Key Opinion Leaders to Discuss Potential Novel Indications for Its FPC Platform
WIXOM, Mich., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around th
Read more →RMTIRockwell Medical, Inc. to Present at Upcoming September Investor Conferences
WIXOM, Mich., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the “Company”), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around th
Read more →RMTIRockwell Medical, Inc. Provides Second Quarter 2020 Financial and Operational Update
-Q2 2020 revenue of $15.9 million- -Increase in contracted clinics of 44 percent quarter-over-quarter- -Reached contracted annualized treatment volume for Triferic Dialysate of over 400,000- - $40.0 million in cash, cash equivalents and investments available-for-sale as of Jun
Read more →RMTIRockwell Medical, Inc.
Rockwell Medical, Inc. Provides Second Quarter 2020 Financial and Operational Update -Q2 2020 revenue of $15.9 million- -Increase in contracted clinics of 44 percent quarter-over-quarter- -Reached contracted annualized treatment volume for Triferic Dialysate of over 400,000-
Read more →RMTIRockwell Medical to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights
WIXOM, Mich., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced that it will
Read more →RMTIUNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK IN RE ROCKWELL MEDICAL, INC. STOCKHOLDER DERIVATIVE LITIGATION Lead Case No. 1:19-cv-02373-ARR-RER (Consolidated with Case No. 1:19-cv-02774-ARR-RER) This Documen
UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK IN RE ROCKWELL MEDICAL, INC. STOCKHOLDER DERIVATIVE LITIGATION Lead Case No. 1:19-cv-02373-ARR-RER (Consolidated with Case No. 1:19-cv-02774-ARR-RER) This Document Relates To: ALL ACTIONS. Honorable Allyne R. Ross NOTICE
Read more →RMTIRockwell Medical, Inc. Appoints Dr. Allen R. Nissenson to Board of Directors
WIXOM, Mich., June 10, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced the appointme
Read more →RMTIRockwell Medical, Inc. Files New Drug Submission with Health Canada for Marketing Approval of Triferic AVNU™
WIXOM, Mich., May 26, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced the filing of
Read more →RMTIRockwell Medical, Inc. Provides First Quarter 2020 Financial and Operational Update and Top-line Real-World Triferic Data
-Q1 2020 revenue of $15.9 million- -Received FDA Approval of Triferic® AVNUTM- -Significant expansion of Triferic (ferric pyrophosphate citrate) Dialysate Evaluation Programs during Q1 2020- -Retrospective real-world analysis over 18 months shows reduction in ESA and tradition
Read more →RMTIRockwell Medical, Inc. Appoints Russell H. Ellison, M.D., M.Sc., as President and Chief Executive Officer --Company to Host Q1 2020 Earnings and Corporate Update Call and Webcast on
Rockwell Medical, Inc. Appoints Russell H. Ellison, M.D., M.Sc., as President and Chief Executive Officer --Company to Host Q1 2020 Earnings and Corporate Update Call and Webcast on May 11, 2020, at 4:30 p.m. ET-- WIXOM, Mich., April 20, 2020 (GLOBE NEWSWIRE) -- Rockwell Medica
Read more →RMTIRockwell Medical, Inc. Appoints Pharmaceutical Industry Leader Robert S. Radie to Board of Directors
WIXOM, Mich., March 31, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, announced today the appointme
Read more →RMTIRockwell Medical, Inc. Receives FDA Approval for Triferic AVNU (Ferric Pyrophosphate Citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialys
Rockwell Medical, Inc. Receives FDA Approval for Triferic AVNU (Ferric Pyrophosphate Citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients - Enhances Triferic platform by providing patients with greater ac
Read more →RMTIRockwell Medical, Inc. Receives FDA Approval for Triferic AVNU (Ferric Pyrophosphate Citrate), Intravenous Formulation of Triferic for Replacement of Iron and Maintenance of Hemoglobin in Hemodialysis Patients
– Enhances Triferic platform by providing patients with greater access to Rockwell Medical’s innovative therapeutic by expanding administration options for clinicians – – Major milestone supports the potential for expanding global adoption of Triferic and transforming the standa
Read more →RMTIRockwell Medical, Inc. Confirms Medical Resource Acquisition Group’s Director Nominations Are Invalid
WIXOM, Mich., March 20, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today reiterated that Medical
Read more →RMTIRockwell Medical, Inc. Announces $35 Million Debt Financing Agreement with Innovatus Capital Partners, LLC - First $22.5 million tranche funded at closing
Medical, Inc. Announces $35 Million Debt Financing Agreement with Innovatus Capital Partners, LLC - First $22.5 million tranche funded at closing - Mich., March 17, 2020 - Rockwell Medical, Inc. (NASDAQ:RMTI) ("Rockwell Medical" or the "Company"), a biopharmaceutical company d
Read more →RMTIRockwell Medical, Inc. Announces $35 Million Debt Financing Agreement with Innovatus Capital Partners, LLC
WIXOM, Mich., March 17, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) ("Rockwell Medical" or the "Company"), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced that it has e
Read more →RMTIRockwell Medical, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results
– Company reports positive adoption trends for Dialysate Triferic® (ferric pyrophosphate citrate), highlighted by 77% increase in clinics under contract – -- Signed contract with a Medium-Sized Dialysis Organization (MDO) for the purchase of Dialysate Triferic; provides access t
Read more →RMTIRockwell Medical, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results - Company reports positive adoption trends for Dialysate Triferic (ferric pyrophosphate citrate), highlighted by 77
Rockwell Medical, Inc. Reports Fourth Quarter and Full Year 2019 Financial Results - Company reports positive adoption trends for Dialysate Triferic (ferric pyrophosphate citrate), highlighted by 77% increase in clinics under contract - -- Signed contract with a Medium-Sized
Read more →RMTIRockwell Medical Determines Medical Resource Acquisition Group’s Director Nominations Are Invalid
WIXOM, Mich., March 11, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced that its Boar
Read more →RMTIRockwell Medical Acknowledges Receipt of Communications from Medical Resource Acquisition Group
WIXOM, Mich., March 10, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today issued the following st
Read more →RMTIRockwell Medical, Inc. Offered $15 Million by Medical Resource Acquisition Group, LLC
NEW YORK, March 09, 2020 (GLOBE NEWSWIRE) -- Medical Resource Acquisition Group, LLC, (MRAG), an investment firm focused on disruptive technologies in the healthcare space, offered Rockwell Medical, Inc. (NASDAQ: RMTI), on February 25, 2020, equity funding of $15 million for the
Read more →RMTIRockwell Medical, Inc. to Discuss Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
WIXOM, Mich., March 04, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. ("Rockwell Medical" or the “Company”) (Nasdaq: RMTI) today announced that the Company will release its 2019 fourth quarter and full year financial results on Thursday, March 12, 2020, after the close of the U
Read more →RMTIRockwell Medical, Inc. Provides Business Update
-- Continued progress for Triferic® portfolio -- -- 77% increase in the number of clinics under contract -- WIXOM, Mich., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to trans
Read more →RMTIRockwell Medical, Inc. to Present at 2020 BIO CEO & Investor Conference
WIXOM, Mich., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, will present at the 2020 BIO CEO & Investor Conference as follows: Date: Monday, February 10, 20
Read more →RMTIRockwell Medical Announces Pricing of $7.5 Million Public Offering of Common Stock
WIXOM, Mich., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced the pricing of
Read more →RMTIRockwell Medical Announces Proposed Public Offering of Common Stock
WIXOM, Mich., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced an underwritte
Read more →RMTIRockwell Medical, Inc. Enters into Exclusive License and Supply Agreements with Sun Pharma for the Rights to Commercialize Triferic in India
WIXOM, Mich., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, today announced that it has en
Read more →RMTIJANUARY 2020 Certain statements in this presentation may constitute "forward - looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell Medical's intention to bring t
Certain statements in this presentation may constitute "forward - looking statements" within the meaning of the federal securities laws, including, but not limited to, Rockwell Medical's intention to bring to market Triferic , and I.V. Triferic . W ords such as "may," "might," "w
Read more →RMTIRockwell Medical, Inc. Enters into Exclusive License and Supply Agreements with Sun Pharma for the Rights to Commercialize Triferic in India - Sizable and growing market opportunity with 120,000+ pa
Medical, Inc. Enters into Exclusive License and Supply Agreements with Sun Pharma for the Rights to Commercialize - Sizable and growing market opportunity with 120,000+ patients receiving hemodialysis annually - WIXOM, Mich., January 14, 2020 - Rockwell Medical, Inc. (NASDAQ
Read more →RMTIRockwell Medical, Inc. Appoints Russell H. Ellison, MD, MSc, to Board of Directors
WIXOM, Mich., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to transforming anemia management and improving outcomes for patients around the world, announced today the appointmen
Read more →RMTIRockwell Medical, Inc. to Present at Biotech Showcase 2020
WIXOM, Mich., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, and Angus Smith, Chief Financial Officer, will present at the Biotech Showcase 2020 as follows:
Read more →RMTIRockwell Medical, Inc. to Present at 31st Annual Piper Jaffray Healthcare Conference
WIXOM, Mich., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, will present at the 31st Annual Piper Jaffray Healthcare Conference as follows: Date: Tuesday, D
Read more →RMTIRockwell Medical, Inc. Expands Medical Capabilities
– Company adds experienced medical executive to management team and leading nephrologists to Medical Advisory Board – – Objective to become a leading medical organization in the field of dialysis – WIXOM, Mich., Nov. 20, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:R
Read more →RMTIRockwell Medical, Inc. Reports Third Quarter 2019 Financial Results
– Company reports first full quarter of results for Dialysate Triferic, highlighted by greater than 75% conversion rate from Triferic Evaluation Program – – Signs leading East Coast academic medical center as first Center of Excellence – WIXOM, Mich., Nov. 11, 2019 (GLOBE NEWSW
Read more →RMTIRockwell Medical, Inc. Reports Third Quarter 2019 Financial Results – Company reports first full quarter of results for Dialysate Triferic, highlighted by greater than 75% conversion rate fro
Rockwell Medical, Inc. Reports Third Quarter 2019 Financial Results Company reports first full quarter of results for Dialysate Triferic, highlighted by greater than 75% conversion rate from Triferic Evaluation Program Signs leading East Coast academic medical center as first C
Read more →RMTIRockwell Medical, Inc. to Sponsor Triferic Exhibitor Spotlight Presentation at American Society of Nephrology Conference
WIXOM, Mich., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD), today announc
Read more →RMTIRockwell Medical, Inc. to Discuss Third Quarter 2019 Financial Results on November 11, 2019
WIXOM, Mich., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (“Rockwell Medical” or the “Company”) (Nasdaq: RMTI) today announced that the Company will release its 2019 third quarter financial results on Monday, November 11, 2019, after the close of the U.S. financial m
Read more →RMTIRockwell Medical, Inc. Appoints John P. McLaughlin Chairman of the Board of Directors
WIXOM, Mich., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD), today announc
Read more →RMTIRockwell Medical, Inc. Provides Business Update Encouraging progress for Triferic portfolio Conference call at 8:30 am ET on Friday
Rockwell Medical, Inc. Provides Business Update Encouraging progress for Triferic portfolio Conference call at 8:30 am ET on Friday, October 25, 2019 WIXOM, Mich., October 24, 2019 Rockwell Medical, Inc. (NASDAQ:RMTI) ( Rockwell Medical or the Company ), a biopharmaceutical co
Read more →RMTIRockwell Medical, Inc. to Present at 2019 Cantor Global Healthcare Conference
WIXOM, Mich., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, is scheduled to present at the 2019 Cantor Global Healthcare Conference as follows: Date: Wedne
Read more →RMTIRockwell Medical, Inc. Appoints Industry Veteran John P. McLaughlin to Board of Directors
WIXOM, Mich., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD) and chronic k
Read more →RMTIRockwell Medical, Inc. to Present at Upcoming September Conferences
WIXOM, Mich., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, is scheduled to present at two upcoming conferences as follows: Conference NewsMakers in the Bio
Read more →RMTIRockwell Medical, Inc. Reports Second Quarter 2019 Financial Results Company Records First Commercial Sales of Dialysate Triferic ; FDA Accepts New Drug Application for I.V. Triferic with PDUFA date
Rockwell Medical, Inc. Reports Second Quarter 2019 Financial Results Company Records First Commercial Sales of Dialysate Triferic ; FDA Accepts New Drug Application for I.V. Triferic with PDUFA date of March 28, 2020 WIXOM, Mich., August 8, 2019 Rockwell Medical, Inc. (NASDAQ:
Read more →RMTIRockwell Medical, Inc. Reports Second Quarter 2019 Financial Results
– Company Records First Commercial Sales of Dialysate Triferic®; FDA Accepts New Drug Application for I.V. Triferic with PDUFA date of March 28, 2020 – WIXOM, Mich., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a b
Read more →RMTIRockwell Medical, Inc. Announces Completion of Two Clinical Pharmacology Studies of TRIFERIC in China
– Positive data suggests no ethnic difference in Triferic PK in Chinese subjects compared to U.S. subjects – – China studies indicate similar delivery of iron via dialysate as in U.S. studies – WIXOM, Mich., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI)
Read more →RMTIRockwell Medical, Inc. Announces Acceptance by FDA of New Drug Application for I.V. TRIFERIC
WIXOM, Mich., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) ("Rockwell Medical" or the "Company"), a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD) and chronic ki
Read more →RMTIRockwell Medical, Inc. to Discuss Second Quarter 2019 Financial Results on August 8, 2019
WIXOM, Mich., July 29, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. ("Rockwell Medical" or the “Company”) (Nasdaq: RMTI) today announced that the Company will release its 2019 second quarter financial results on Thursday, August 8, 2019, after the close of the U.S. financial m
Read more →RMTIRockwell Medical Announces Pricing of $17.5 Million Public Offering of Common Stock
WIXOM, Mich., June 18, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD) and chronic ki
Read more →RMTIRockwell Medical Announces Adjournment of Annual Meeting of Shareholders
- Adjournment solely to vote on Delaware reincorporation Proposal 3(a) - - Both leading independent advisory firms have issued favorable recommendations on proposal - WIXOM, Mich., June 07, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the
Read more →RMTIRockwell Medical, Inc. Announces Submission of New Drug Application for I.V. Triferic
WIXOM, Mich., May 29, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) ("Rockwell Medical" or the "Company"), a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD) and chronic kid
Read more →RMTIRockwell Medical, Inc. Reports First Quarter 2019 Financial Results
WIXOM, Mich., May 09, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the "Company"), a biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD) and chronic kid
Read more →RMTIRockwell Medical, Inc. Reports First Quarter 2019 Financial Results Significant progress for portfolio of Triferic therapeutics marked by launch of Dialysate Triferic
Rockwell Medical, Inc. Reports First Quarter 2019 Financial Results Significant progress for portfolio of Triferic therapeutics marked by launch of Dialysate Triferic WIXOM, Mich., May 9, 2019 Rockwell Medical, Inc. (NASDAQ:RMTI) ( Rockwell Medical or the Company ), a biopharma
Read more →RMTIRockwell Medical, Inc. Commences Commercial Sales of Dialysate Triferic in the U.S.
WIXOM, Mich., May 06, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the “Company”), a global biopharmaceutical company dedicated to improving outcomes for patients with anemia, with an initial focus on end-stage renal disease (ESRD) and chro
Read more →RMTIRockwell Medical, Inc. to Discuss First Quarter 2019 Financial Results on May 9, 2019
WIXOM, Mich., May 02, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. ("Rockwell Medical" or the “Company”) (Nasdaq: RMTI) today announced that the Company will release its 2019 first quarter financial results on Thursday, May 9, 2019, after the closing of the U.S. financial mark
Read more →RMTIRockwell Medical, Inc. to Present at H.C Wainwright Global Life Sciences Conference
WIXOM, Mich., April 03, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, will present at the H.C Wainwright Global Life Sciences Conference as follows: Date: Monday, Ap
Read more →RMTIRockwell Medical, Inc. to Present at Sidoti & Company LLC Spring 2019 Investor Conference
WIXOM, Mich., March 20, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, will present at the Sidoti & Company LLC Spring 2019 Investor Conference as follows: Date: Thu
Read more →RMTIRockwell Medical Announces I.V. Triferic and Peritoneal Dialysis Study Abstracts Selected as Best-in-Category at the Annual Dialysis Conference
I.V. Triferic Data to Support Upcoming New Drug Application Intraperitoneal Triferic Effectively Delivers Iron to Patients with Kidney Failure in Outpatient Setting WIXOM, Mich., March 18, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) (“Rockwell Medical” or the
Read more →RMTIRockwell Medical, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results
WIXOM, Mich., March 14, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) (the "Company"), a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD), today reported financial results for the three months and full year ended
Read more →RMTIRockwell Medical, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results Company is poised to advance multiple formulations of Triferic , the first and only FDA-approved therapy indicated
Rockwell Medical, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results Company is poised to advance multiple formulations of Triferic , the first and only FDA-approved therapy indicated to replace iron and maintain hemoglobin levels in adult hemodialysis patients WI
Read more →RMTIRockwell Medical, Inc. to Discuss Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019
WIXOM, Mich., March 06, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. ("Rockwell Medical" or the “Company”) (Nasdaq: RMTI) today announced that the Company will release its 2018 fourth quarter and full year financial results on Thursday, March 14, 2019, before the opening of th
Read more →RMTITranscript of Rockwell Medical, lnc. Presentation at the 2019 BIO CEO & lnvestor Conference
Rockwell Medical, lnc. Presentation at the 2019 Female Speaker: I would like to introduce Rockwell Biopharmaceutical right now. Paul Stuart is here, the president and CEO. Stuart Paul: Thank you, good afternoon. Thanks for joining us and thanks for being here for the presentati
Read more →RMTIRockwell Medical, Inc. to Present at 2019 BIO CEO & Investor Conference
WIXOM, Mich., Feb. 05, 2019 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, will present at the 2019 BIO CEO & Investor Conference as follows: Date: Monday, February 11, 20
Read more →RMTIRockwell Medical Investor Presentation January 2019 Certain statements in this presentation may constitute forward-looking statements within the meaning of the federal securities laws. Words such as may, might, will, sho
Rockwell Medical Investor Presentation January 2019 Certain statements in this presentation may constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate
Read more →RMTIRockwell Medical, Inc. to Present at Biotech Showcase™ 2019
WIXOM, Mich., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ: RMTI) ("Rockwell Medical" or the "Company") today announced that Stuart Paul, Chief Executive Officer, will present at Biotech Showcase™ 2019 during the J.P. Morgan Annual Healthcare Conference as fol
Read more →RMTIRockwell Medical, Inc. Reports Third Quarter 2018 Financial Results
Rockwell Medical, Inc. Reports Third Quarter 2018 Financial Results WIXOM, Mich., Nov. 9, 2018 /PRNewswire/ Rockwell Medical, Inc. (NASDAQ: RMTI) (the Company ) today reported financial results for the third quarter ended September 30, 2018, and highlighted recent and upcoming c
Read more →RMTIRockwell Medical, Inc. Provides Business Update, Reports Second Quarter 2018 Financial Results and Restates First Quarter 2018 Financial Results
Rockwell Medical, Inc. Provides Business Update, Reports Second Quarter 2018 Financial Results and Restates First Quarter 2018 Financial Results WIXOM, Mich., August 14, 2018 Rockwell Medical, Inc. (NASDAQ:RMTI) (the Company ) today provided a business update, financial results
Read more →RMTIROCKWELL MEDICAL, INC. INVESTOR ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York against Rockwell Medical, Inc.
NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces the filing of a class action lawsuit on behalf of purchasers of the securities of Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell”) between March 16, 2018 and June 26, 2018, inclusive
Read more →RMTIRockwell Medical Appoints New Chief Executive Officer Stuart Paul Brings Significant Healthcare Experience
Rockwell Medical Appoints New Chief Executive Officer Stuart Paul Brings Significant Healthcare Experience WIXOM, Mich., August 8, 2018 Rockwell Medical, Inc. (NASDAQ:RMTI) (the Company or Rockwell Medical ) today announced that its Board of Directors has appointed Stuart Paul
Read more →RMTIRockwell Class Action: Bernstein Liebhard LLP Files Securities Class Action Lawsuit Against Rockwell Medical, Inc. - RMTI
NEW YORK, Aug. 05, 2018 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, has filed a securities class action lawsuit on behalf of those who purchased or acquired the securities of Rockwell Medical, Inc. (“Rockwell” or the “Company”) (NA
Read more →RMTIRockwell Notice: Bernstein Liebhard LLP Files Securities Class Action Lawsuit Against Rockwell Medical, Inc. - RMTI
NEW YORK, July 31, 2018 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, has filed a securities class action lawsuit on behalf of those who purchased or acquired the securities of Rockwell Medical, Inc. (“Rockwell” or the “Company”) (NA
Read more →RMTIRockwell Medical Announces Engagement of Marcum LLP as New Independent Auditor
Rockwell Medical Announces Engagement of Marcum LLP as New Independent Auditor WIXOM, Mich., July 30, 2018 Rockwell Medical, Inc. (NASDAQ:RMTI) (the Company ) today announced that the Audit Committee of its Board of Directors has engaged Marcum LLP as Rockwell Medical s new inde
Read more →RMTIRockwell Shareholder Alert: Bernstein Liebhard LLP Announces Investigation of Rockwell Medical, Inc. - RMTI
NEW YORK, July 18, 2018 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Rockwell Medical, Inc. (“Rockwell” or the “Company”) (NASDAQ:RMTI) resulting from a
Read more →RMTISTATE OF MICHIGAN IN THE CIRCUIT COURT FOR THE COUNTY OF OAKLAND ROCKWELL MEDICAL, INC., Plaintiff, Case No. 2018-165893-CB v. Ron. Wendy Potts ROBERT CHIOINI and THOMAS KLEMA, Defendants. ORDER REGARDING APPROVAL OF TER
STATE OF MICHIGAN IN THE CIRCUIT COURT FOR THE COUNTY OF OAKLAND ROCKWELL MEDICAL, INC., Plaintiff, Case No. 2018-165893-CB v. Ron. Wendy Potts ROBERT CHIOINI and THOMAS KLEMA, Defendants. ORDER REGARDING APPROVAL OF TERM SHEET AND DISMISSAL OF LITIGATION WITHOUT PREJUDICE At a s
Read more →RMTISTATE OF MICHIGAN IN THE CIRCUIT COURT FOR THE COUNTY OF OAKLAND ROCKWELL MEDICAL INC Plaintiff, NO: 2018-165893-CB V HON. WENDY POTTS CHIOINI.ROBERT,, Defendant, In the matter of: ORDER REGARDING MOTION Motion Title: Mo
STATE OF MICHIGAN IN THE CIRCUIT COURT FOR THE COUNTY OF OAKLAND ROCKWELL MEDICAL INC Plaintiff, NO: 2018-165893-CB V HON. WENDY POTTS CHIOINI.ROBERT,, Defendant, ORDER REGARDING MOTION Motion Title: Motion to Enforce Status Quo Order and Objection to Entry of Amended Order
Read more →RMTIRockwell Medical Provides Update on Commercial Strategy Company to Move Forward with Commercialization of Triferic
Rockwell Medical Provides Update on Commercial Strategy Company to Move Forward with Commercialization of Triferic WIXOM, Mich., June 7, 2018 - Rockwell Medical, Inc. (NASDAQ: RMTI) ( the Company ) today provided an update on the Company s commercial strategy for its innovative
Read more →RMTIRockwell Medical CEO Issues Press Release
WIXOM, Mich., May 23, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated specialty pharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron repla
Read more →RMTISTATE OF MICHIGAN IN THE CIRCUIT COURT FOR THE COUNTY OF OAKLAND ROCKWELL MEDICAL, INC., Plaintiff, Case No. 2018-165893-CB vs. Hon. Wendy Potts ROBERT CHIOINI and THOMAS KLEMA, Defendants. I ----------------------------
STATE OF MICHIGAN IN THE CIRCUIT COURT FOR THE COUNTY OF OAKLAND ROCKWELL MEDICAL, INC., Plaintiff, Case No. 2018-165893-CB vs. Hon. Wendy Potts ROBERT CHIOINI and THOMAS KLEMA, Defendants. I -----------------------------------------------------------------John R. Trentacosta (P3
Read more →RMTIRockwell Medical Announces CEO Transition
Rockwell Medical Announces CEO Transition Special Transition Committee Established; Permanent CEO Search Underway Company Reiterates Recently Reported Financial Results and Cash Position WIXOM, Mich., May 22, 2018 /PRNewswire/ Rockwell Medical, Inc. (NASDAQ: RMTI) ( the Compan
Read more →RMTIRockwell Medical Reports First Quarter 2018 Results
Conference call at 4:30 p.m. EDT today, May 10 WIXOM, Mich., May 10, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated specialty pharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative produ
Read more →RMTIRockwell Medical Update on Calcitriol New Manufacturing Submission to FDA
WIXOM, Mich., May 08, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), today provided an update on its new manufacturing submission for its Calcitriol vitamin D injection, stating that the FDA has provided a target date for a response to the submission of no later t
Read more →RMTIRockwell Medical Schedules First Quarter 2018 Earnings Call
WIXOM, Mich., May 02, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hy
Read more →RMTIRockwell Medical Announces Triferic Presentations at the 2018 International Congress on Peritoneal Dialysis
Conference to be held May 5-8, in Vancouver, Canada WIXOM, Mich., May 02, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), announced today that two Triferic® abstracts have been selected for presentation at the 17th Congress of the International Society for Periton
Read more →RMTIRockwell Medical Announces Triferic Presentations at the 2018 National Kidney Foundation Spring Clinical Meetings
Three Poster Presentations with Data for Triferic Clinical Pharmacology and Peritoneal Dialysis Conference being held April 11-14 in Austin, TX WIXOM, Mich., April 05, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), announced today that three Triferic abstracts
Read more →RMTIRockwell Medical Announces Triferic Presentations at the 2018 Asia Pacific Congress of Nephrology
Oral and Poster Presentations for Triferic Clinical Pharmacology and Peritoneal Dialysis Conference being held March 27-31, 2018, in Beijing China WIXOM, Mich., March 20, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), announced today that four Triferic abstracts
Read more →RMTIRockwell Medical Reports Fourth Quarter and Year End 2017 Results
Conference call at 4:30 p.m. EDT today WIXOM, Mich., March 15, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and servi
Read more →RMTIRockwell Medical, Inc. Appoints Two Independent and Experienced Life Sciences Executives to Board of Directors
Lisa Colleran and Benjamin Wolin Unanimously Appointed to Rockwell Board Wolin Named Chairman of the Board Company Reaches Support Agreement with Richmond Brothers WIXOM, Mich., March 13, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), (the “Company”) announced
Read more →RMTIROCKWELL MEDICAL, INC. APPOINTS TWO INDEPENDENT AND EXPERIENCED LIFE SCIENCES EXECUTIVES TO BOARD OF DIRECTORS Lisa Colleran and Benjamin Wolin Unanimously Appointed to Rockwell Board Wolin Named Chairman o
ROCKWELL MEDICAL, INC. APPOINTS TWO INDEPENDENT AND EXPERIENCED LIFE SCIENCES EXECUTIVES TO BOARD OF DIRECTORS Lisa Colleran and Benjamin Wolin Unanimously Appointed to Rockwell Board Wolin Named Chairman of the Board Company Reaches Support Agreement with Richmond Brothers W
Read more →RMTIRockwell Medical Schedules Year End 2017 Earnings Call
WIXOM, Mich., March 12, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary
Read more →RMTIRockwell Medical Announces Triferic Presentations at the 2018 Annual Dialysis Conference
Oral and poster presentation of data for Triferic in pediatric patients and patients on intraperitoneal dialysis Conference being held March 3-6, 2018, in Orlando, Fla. WIXOM, Mich., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), announced today that tw
Read more →RMTIRockwell Medical Signs Exclusive License Agreement with Comercializadora BioRenal SpA to Commercialize Triferic in Chile
- Estimated Market Launch 2nd-half 2018 Provides Access to 20,000 Dialysis Patients - WIXOM, Mich., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), announced today that it has signed an exclusive license and manufacturing supply agreement with privately h
Read more →RMTIRockwell Medical Signs Exclusive License Agreement with Quimica Europea to Commercialize Triferic in Peru
- Estimated Market Launch 2nd-half 2018 Provides Access to 13,000 Dialysis Patients - WIXOM, Mich., Dec. 12, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), announced today that it has signed an exclusive license and manufacturing supply agreement with privately h
Read more →RMTIRockwell Medical Reports Third Quarter Results
Conference Call and Webcast Today at 4:30 p.m. EST. WIXOM, Mich., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), reported results for the three and nine months ended Sept. 30, 2017. Q3 2017 Financial Highlights Sales were $14.6 million, an increase of
Read more →RMTIRockwell Medical Schedules Third Quarter 2017 Earnings Call
WIXOM, Mich., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary h
Read more →RMTIRockwell Medical Announces Two Triferic Poster Presentations at American Society of Nephrology Kidney Week 2017 Annual Meeting
WIXOM, Mich., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), announced today that two poster presentations for Triferic have been selected by the American Society of Nephrology (ASN) for presentation at the annual Kidney Week meeting Nov. 1-5, 2017, in Ne
Read more →RMTIRockwell Update on Calcitriol Post-Approval Manufacturing Submission to FDA
WIXOM, Mich., Oct. 25, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), today provided an update on the commercial launch of Calcitriol, stating that the FDA has requested extra time to review its post-approval drug manufacturing submission that was filed with the F
Read more →RMTIRockwell Files Calcitriol Post-Approval Manufacturing Submission with FDA
WIXOM, Mich., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), today provided an update on the commercial launch of Calcitriol, stating that it has submitted its chemistry, manufacturing and controls (CMC) post-approval drug manufacturing supplement to the
Read more →RMTIRockwell Medical Updates Progress on Calcitriol Commercial Launch
WIXOM, Mich., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), today provided an update on the commercial launch of Calcitriol, stating that product stability data for manufacturing approval is suitable for submission to the FDA. The Company plans to subm
Read more →RMTIRockwell Medical Appoints John G. Cooper to Board of Directors
WIXOM, Mich., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary
Read more →RMTIRockwell Medical Responds to Richmond Group
WIXOM, Mich., Aug. 29, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) today issued the following statement concerning the Richmond Group’s filing of an amended Schedule 13D with the Securities and Exchange Commission yesterday: Since the annual meeting of sharehol
Read more →RMTIRockwell Medical Reports Second Quarter Results
WIXOM, Mich., Aug. 09, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary h
Read more →RMTIRockwell Medical Schedules Second Quarter 2017 Earnings Call
WIXOM, Mich., Aug. 04, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary h
Read more →RMTIRockwell Medical Announces Triferic Presentation at Annual Conference on Nephrology & Urology July 6-7th, 2017, Kuala Lumpur, Malaysia
WIXOM, Mich., June 28, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary h
Read more →RMTIRockwell Medical Sends Important Message to Richmond Brothers’ Clients: You Have the Sole Authority to Vote Your Own Shares
Reminds Shareholders Not to be Misled by Richmond Brothers’ Previous Claim to Control 11.8% of Rockwell Clarifies that David Richmond and Mark Ravich Each Personally Own Less Than 1% of Rockwell Believes Richmond Brothers Has Made Misleading Statements While Promoting a Self-Se
Read more →RMTIRockwell Medical Issues Letter to Shareholders Explaining Why Electing Mark Ravich Could Do Lasting Harm
WIXOM, Mich., May 22, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) today mailed a letter to its shareholders in connection with the Company’s upcoming 2017 Annual Meeting of Shareholders (“Annual Meeting”) to be held on June 1, 2017. The Rockwell Medical Board o
Read more →RMTIRockwell Medical Encourages Shareholders Not to Be Misled by Richmond Brothers
Issues Letter to Shareholders Setting the Record Straight Urges Shareholders to Vote “FOR” David Domzalski on the WHITE Proxy Card WIXOM, Mich., May 16, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) today mailed a letter to its shareholders in connection with th
Read more →RMTIRockwell Medical Files Investor Presentation
Rockwell Is Executing the Optimal Strategy for Shareholders David Domzalski Brings the Right Skills to Rockwell Medical’s Board for Generating Superior Value Rockwell Medical Urges Shareholders to Vote “FOR” David Domzalski and All Other Proposals on the WHITE Proxy Card WIXOM
Read more →RMTIRockwell Medical 1Q17 Earnings Call
Rockwell Medical 1Q17 Earnings Call Paul Arndt; LifeSci Advisors Rob Chioini; Rockwell Medical; Chairman, CEO Tom Klema; Rockwell Medical; CFO Charles Haff; Craig-Hallum; Analyst Operator: Good day, everyone. Welcome to the Rockwell Medical First Quarter 2017 Earnings Call.
Read more →RMTIRockwell Medical Reports First Quarter Results
WIXOM, Mich., May 09, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hy
Read more →RMTIRockwell Medical Shareholders Express Support for the Election of David Domzalski
WIXOM, Mich., May 09, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) today released several statements of support from shareholders in connection with the Company’s upcoming 2017 Annual Meeting of Shareholders (“Annual Meeting”) to be held on June 1, 2017. Dianne
Read more →RMTIRockwell Medical Schedules First Quarter 2017 Earnings Call
WIXOM, Mich., May 05, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary hy
Read more →RMTIRockwell Medical Mails Letter to Shareholders Profiling Independent Director Nominee David Domzalski
Highlights Mr. Domzalski’s Experience Building Commercial Organizations and Launching New Drugs Urges Shareholders to Vote “FOR” David Domzalski on the WHITE Proxy Card WIXOM, Mich., May 04, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI) today mailed a letter to
Read more →RMTIRockwell Medical Announces Poster Presentation and Oral Presentation on Triferic at the 7th Congress of the International BioIron Society May 7 – 11, 2017
WIXOM, Mich., April 27, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary
Read more →RMTIRockwell Medical Files Definitive Proxy Materials
Mails Letter to Shareholders Highlighting Substantial Commercial Progress and Importance of Electing a Director with Relevant Pharmaceutical Expertise Urges Shareholders to Vote “FOR” Rockwell Medical’s Highly-Qualified Director Nominee David Domzalski on the WHITE Proxy Card W
Read more →RMTIRockwell Medical Announces Triferic Poster Presentations at the National Kidney Foundation (NKF) Spring Clinical Meeting in Orlando, FL April 18-22, 2017
WIXOM, Mich., April 10, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary
Read more →RMTIRockwell Medical Files Preliminary Proxy Statement for Annual Meeting - New Director Nominated, Lead Independent Director Named, Corporate Governance Enhancements Instituted - WIXOM, MICHIGAN
Rockwell Medical Files Preliminary Proxy Statement - New Director Nominated, Lead Independent Director Named, Corporate Governance Enhancements Instituted - WIXOM, MICHIGAN, April 4, 2017 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targe
Read more →RMTIRockwell Medical Files Preliminary Proxy Statement for Annual Meeting
WIXOM, Mich., April 04, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary
Read more →RMTIRockwell Medical Announces ESA Sparing, Compositions and Use Patent Allowed in China
WIXOM, Mich., March 28, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary
Read more →RMTIRockwell Medical Reports Fourth Quarter Results
WIXOM, Mich., March 15, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacemen
Read more →RMTIRockwell Medical Schedules Fourth Quarter & Year End 2016 Earnings Call
WIXOM, Mich., March 13, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary
Read more →RMTIRockwell Medical Announces One Poster and Two Oral Presentations on Triferic at Annual Dialysis Conference March 11th-14th in Long Beach, CA
WIXOM, Mich., March 06, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary
Read more →RMTIRockwell Medical Announces Nomination of David Domzalski to Board of Directors
WIXOM, Mich., March 02, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary
Read more →RMTIRockwell Medical Announces Nomination of Dave Domzalski to Board of Directors WIXOM, MICHIGAN
Rockwell Medical Announces Nomination of Dave Domzalski to Board of Directors WIXOM, MICHIGAN, March 2, 2017 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innova
Read more →RMTIRockwell Medical will Present Data on Triferic Intravenous (IV) Administration at the 19th International Conference on Dialysis in Las Vegas, February 1-3, 2017
WIXOM, Mich., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary h
Read more →RMTIRockwell Medical Schedules Third Quarter 2016 Earnings Call
WIXOM, Mich., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary h
Read more →RMTIRockwell Medical to Present Data on Peritoneal Dialysis (PD) Administration of Triferic at American Society of Nephrology (ASN) Meeting November 2016
WIXOM, Mich., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary h
Read more →RMTIRockwell Medical Announces Triferic Human Intravenous (IV) Pharmacokinetic Study Published in Journal of Clinical Pharmacology
WIXOM, Mich., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary h
Read more →RMTIRockwell Medical Preparing for Calcitriol Commercial Launch
WIXOM, Mich., Sept. 22, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products for the treatment of iron replacement, secondary
Read more →RMTIRockwell Medical Enters into Exclusive License Agreement with ARAM Medical to Commercialize Triferic in Saudi Arabia, Egypt and Middle East Territories
- Territory Covers 375,000 CKD-HD patients; Rockwell Receives Upfront Licensing Fee, High Double-digit Royalty and Annual Contractual Minimum Product Purchases - WIXOM, Mich., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmace
Read more →RMTIRockwell Medical Schedules Second Quarter 2016 Earnings Call
WIXOM, Mich., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Announces Appointment of Dr. Robin Smith to Board of Directors
WIXOM, Mich., June 23, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Announces Multiple International Trademark Approvals for Triferic
WIXOM, Mich., May 12, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Schedules First Quarter 2016 Earnings Call
WIXOM, Mich., May 05, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Provides Update on Preparations for Calcitriol Commercial Launch
WIXOM, Mich., May 04, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Announces Triferic Presentation “Overcoming Functional Iron Deficiency in Your Hemodialysis Patients” at the National Kidney Foundation (NKF) Spring Clinical Meeting in Boston, MA April 29, 2016
WIXOM, Mich., April 28, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacemen
Read more →RMTIRockwell Medical Reports Fourth Quarter and Fiscal 2015 Results
WIXOM, Mich., Feb. 29, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Schedules Fourth Quarter & Fiscal 2015 Earnings Call
WIXOM, Mich., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Files IND to Investigate Triferic for Rare Orphan Disease Iron-Refractory, Iron-Deficiency Anemia (IRIDA)
WIXOM, Mich., Feb. 22, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Enters Into Exclusive License Agreement With Wanbang Biopharmaceutical Co., Ltd. to Commercialize Triferic in China
WIXOM, Mich., Feb. 16, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Announces Two Triferic Poster Presentations Accepted for Presentation at National Kidney Foundation Spring Clinical Meetings April 27 – May 1, 2016 in Boston, MA
WIXOM, Mich., Jan. 19, 2016 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical to Present at Oppenheimer 26th Annual Healthcare Conference
WIXOM, Mich., Dec. 1, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical's Triferic Receives Permanent J-Code for Renal Drug Reimbursement
WIXOM, Mich., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical to Present at Stifel 2015 Healthcare Conference
WIXOM, Mich., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Reports Third Quarter 2015 Results
WIXOM, Mich., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Schedules Third Quarter Earnings Call
WIXOM, Mich., Nov. 2, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Announces Presentation Schedule for Triferic Clinical Posters at American Society of Nephrology (ASN) Meeting November 2015
WIXOM, Mich., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Introduces New Video Demonstrating Triferic(R) Mode-of-Action at www.triferic.com
WIXOM, Mich., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Announces Four Triferic Posters Accepted for Presentation at American Society of Nephrology (ASN) Clinical Meeting November 2015
WIXOM, Mich., Oct. 6, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Launches New Triferic(TM) Website
WIXOM, Mich., Oct. 1, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Announces the U.S. Commercial Launch of Triferic(TM)
WIXOM, Mich., Sept. 9, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Reports Second Quarter 2015 Results
WIXOM, Mich., Aug. 4, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Schedules Second Quarter Earnings Call
WIXOM, Mich., July 27, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Announces Triferic(TM) Phase 3 CRUISE Studies Published in Nephrology Dialysis Transplantation
WIXOM, Mich., July 15, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Announces Triferic(TM) ESA-Sparing PRIME Study Published in Kidney International
WIXOM, Mich., July 13, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Announces Triferic Receives Q-Code Assignment for Product Reimbursement
WIXOM, Mich., June 1, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Announces Triferic Clinical Data Selected for Four Presentations at the 52nd ERA-EDTA Congress May 28-31, 2015 in London, UK
WIXOM, Mich., May 12, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Reports First Quarter 2015 Results
WIXOM, Mich., May 7, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical to Present at Bank of America Merrill Lynch 2015 Health Care Conference
WIXOM, Mich., May 5, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Schedules First Quarter Earnings Call
WIXOM, Mich., April 30, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacemen
Read more →RMTIRockwell Medical Announces Triferic(TM) Clinical Data Selected for Four Poster Presentations at National Kidney Foundation Spring Clinical Meetings March 26-29, 2015 in Dallas, Texas
WIXOM, Mich., March 26, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacemen
Read more →RMTIRockwell Medical Reports Fourth Quarter 2014 Results
WIXOM, Mich., Feb. 26, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Schedules Fourth Quarter Earnings Call
WIXOM, Mich., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Announces Two Triferic Abstracts to be Presented at Annual Dialysis Conference Jan. 31 - Feb. 3, 2015 in New Orleans, Louisiana
WIXOM, Mich., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Closes $58.5 Million Public Offering of Common Stock
WIXOM, Mich., Nov. 25, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency,
Read more →RMTIRockwell Medical Prices $58.5 Million Public Offering of Common Stock WIXOM, MI 11/19/2014 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and
Rockwell Medical Prices $58.5 Million Public Offering of Common Stock WIXOM, MI 11/19/2014 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and s
Read more →RMTIRockwell Medical Closes $58.5 Million Public Offering of Common Stock WIXOM, MI 11/25/2014 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and
Rockwell Medical Closes $58.5 Million Public Offering of Common Stock WIXOM, MI 11/25/2014 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and s
Read more →RMTIRockwell Medical Announces $55 million Proposed Public Offering of Common Stock WIXOM, MI (Marketwire) 11/17/2014 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage re
Rockwell Medical Announces $55 million Proposed Public Offering of Common Stock WIXOM, MI (Marketwire) 11/17/2014 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with in
Read more →RMTIRockwell Medical Announces Presentation Schedule for Triferic Clinical Posters at the American Society of Nephrology (ASN) Meeting November 2014
WIXOM, Mich., Nov. 11, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical, Inc. Reports Third Quarter 2014 Results
WIXOM, Mich., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Schedules Third Quarter 2014 Investor Conference Call
WIXOM, Mich., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Announces FDA Advisory Committee Review of Triferic for the Treatment of Iron Replacement and Maintenance of Hemoglobin in Hemodialysis Patients
WIXOM, Mich., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Receives $8 Million in Cash Via Exercise of Warrants
WIXOM, Mich., Oct. 7, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Enters Into Exclusive Long-Term Agreement With Baxter Healthcare to Commercialize Rockwell's Hemodialysis Concentrates
WIXOM, Mich., Oct. 3, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Enters into Exclusive Long-Term Agreement with Baxter Healthcare to Commercialize Rockwell s Hemodialysis Concentrates - Rockwell Receives $20MM Upfront Cash; $15MM Equity Investment; $10MM
Rockwell Medical Enters into Exclusive Long-Term Agreement with Baxter Healthcare to Commercialize Rockwell s Hemodialysis Concentrates - Rockwell Receives $20MM Upfront Cash; $15MM Equity Investment; $10MM in Milestone Payments Tied to Manufacturing Expansion - WIXOM, MICHIGAN
Read more →RMTIRockwell Medical, Inc. Reports Second Quarter 2014 Results
WIXOM, Mich., July 31, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Schedules 2nd Quarter 2014 Investor Conference Call
WIXOM, Mich., July 25, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Announces FDA Approves $2.2 Million Application Fee Refund for Triferic(TM) NDA
WIXOM, Mich., June 30, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Receives FDA Approval for Calcitriol
WIXOM, Mich., June 23, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Wins Appeal for Determination as Small Business for New Drug Application Filing for Triferic(TM)
WIXOM, Mich., June 9, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Announces FDA Acceptance for Filing of Triferic(TM) New Drug Application
WIXOM, Mich., May 28, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical to Participate at Craig-Hallum Institutional Investor Conference Wednesday, May 28, 2014 in Minneapolis, MN
- Management Team to Discuss Triferic Iron Delivery and Business Initiatives - WIXOM, Mich., May 22, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (C
Read more →RMTIRockwell Medical to Present Triferic(TM) Iron Replacement Clinical Data at 51st ERA-EDTA Congress in Amsterdam, The Netherlands, May 31 - June 3, 2014
WIXOM, Mich., May 14, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical, Inc. Reports First Quarter 2014 Results
WIXOM, Mich., May 12, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Schedules 1st Quarter 2014 Investor Conference Call
WIXOM, Mich., May 6, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement,
Read more →RMTIRockwell Medical Announces Triferic(TM) Iron Replacement Clinical Data to be Presented at 14th Asian Pacific Congress of Nephrology May 14-17, 2014 in Tokyo, Japan
WIXOM, Mich., April 29, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacemen
Read more →RMTIRockwell Medical Announces Triferic(TM) Iron Replacement Clinical Data Selected for Three Abstract Presentations at National Kidney Foundation Spring Clinical Meetings April 22-26, 2014 in Las Vegas, NV
WIXOM, Mich., April 14, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacemen
Read more →RMTIRockwell Medical Submits New Drug Application for Triferic(TM) for the Treatment of Iron Replacement in Chronic Kidney Disease Patients on Hemodialysis
WIXOM, Mich., March 24, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacemen
Read more →RMTIRockwell Medical to Host Investor Meeting With Nephrology Key Opinion Leader on March 6, 2014 in New York City
WIXOM, Mich., March 5, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical, Inc. Reports Fourth Quarter 2013 Results
WIXOM, Mich., Feb. 26, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement
Read more →RMTIRockwell Medical Reports Third Quarter 2013 Results
- Successful Triferic Phase 3 Clinical Results Highlight Quarter - - Conference Call 4:15pm Eastern Time - WIXOM, Mich., Nov. 5, 2013 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD)
Read more →RMTIRockwell Medical Reports Second Quarter 2013 Results
- Successful Top Line Data from Phase 3 SFP Study Highlight Quarter - - Conference Call at 4:15pm Eastern Time - WIXOM, Mich., Aug. 1, 2013 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (
Read more →RMTIRockwell Medical Announces SFP Meets Primary and Key Secondary Endpoints in Phase 3 CRUISE-1 Efficacy Study as a Treatment for Iron Replacment in Chronic Kidney Disease Patients on Dialysis - In dialysis pa
Rockwell Medical Announces SFP Meets Primary and Key Secondary Endpoints in Phase 3 CRUISE-1 Efficacy Study as a Treatment for Iron Replacment in Chronic Kidney Disease Patients on Dialysis - In dialysis patients not receiving IV iron, SFP effectively delivers iron via dialys
Read more →RMTIRockwell Medical Closes $40.3 Million Public Offering of Common Stock WIXOM, MI (Globe Newswire) 05/20/2013 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal di
Rockwell Medical Closes $40.3 Million Public Offering of Common Stock WIXOM, MI (Globe Newswire) 05/20/2013 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovati
Read more →RMTIRockwell Medical Announces the Exercise of Over-Allotment Option WIXOM, MI (GLOBE NEWSWIRE) 05/16/13 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (
Rockwell Medical Announces the Exercise of Over-Allotment Option WIXOM, MI (GLOBE NEWSWIRE) 05/16/13 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative prod
Read more →RMTIRockwell Medical Prices $35.0 Million Public Offering of Common Stock WIXOM, MI (Globe Newswire) 05/15/13 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal dise
Rockwell Medical Prices $35.0 Million Public Offering of Common Stock WIXOM, MI (Globe Newswire) 05/15/13 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative
Read more →RMTIRockwell Medical Announces Proposed Public Offering of Common Stock WIXOM, MI (Marketwire) 05/14/13 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (E
Rockwell Medical Announces Proposed Public Offering of Common Stock WIXOM, MI (Marketwire) 05/14/13 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative produ
Read more →RMTIRockwell Medical Reports 2013 First Quarter Results; Signs Long-Term, National Supply Agreement With DaVita
- Compelling PRIME Data, Calcitriol Manufacturing Submission Highlight Q1- - Company to expand business with DaVita via multi-year supply deal - WIXOM, Mich., May 8, 2013 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targ
Read more →RMTIRockwell Medical Announces Long-Term, National Supply Agreement With DaVita
WIXOM, Mich., May 8, 2013 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced
Read more →RMTIRockwell Medical Closes $12.9 Million Registered Direct Common Stock Offering WIXOM, MICHIGAN
Rockwell Medical Closes $12.9 Million Registered Direct Common Stock Offering WIXOM, MICHIGAN, March 26, 2013 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innov
Read more →RMTIRockwell Medical to Raise $12.9 Million in Registered Direct Common Stock Offering WIXOM, MICHIGAN
Rockwell Medical to Raise $12.9 Million in Registered Direct Common Stock Offering WIXOM, MICHIGAN, March 20, 2013 Rockwell Medical, Inc. (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with
Read more →RMTIRockwell Medical to Raise $12.9 Million in Registered Direct Common Stock Offering
WIXOM, Mich., March 20, 2013 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency
Read more →RMTIRockwell Medical Reports 2012 Fourth Quarter and Full Year Results
WIXOM, Mich., March 18, 2013 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency
Read more →RMTIRockwell Medical Schedules Conference Call Reporting Fourth Quarter and 2012 Year End Results
WIXOM, Mich., March 7, 2013 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secon
Read more →RMTIRockwell Medical Announces Iron Delivery Drug SFP Meets Primary Endpoint in PRIME Clinical Study Demonstrating Statistically Significant 37% Reduction in ESA Dose - Unique iron drug maintains hemoglobin whi
Rockwell Medical Announces Iron Delivery Drug SFP Meets in PRIME Clinical Study Demonstrating Statistically Significant 37% Reduction in ESA Dose - Unique iron drug maintains hemoglobin while greatly decreasing need for ESA - WIXOM, MICHIGAN, February 4, 2013 Rockwell Medical
Read more →RMTIRockwell Medical Reports Third Quarter 2012 Results
WIXOM, Mich., Nov. 8, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency,
Read more →RMTIRockwell Medical Schedules Conference Call Reporting Third Quarter Results
WIXOM, Mich., Oct. 22, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secon
Read more →RMTIRockwell Medical Schedules Conference Call Reporting Second Quarter Results
WIXOM, Mich., July 26, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secon
Read more →RMTIRockwell Medical Reports First Quarter 2012 Results
WIXOM, Mich., May 3, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, seconda
Read more →RMTIRockwell Medical Schedules Earnings Conference Call
WIXOM, MI, May 1, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary
Read more →RMTIRockwell Medical Appoints Raymond Pratt, M.D. FACP as Chief Medical Officer
WIXOM, Mich., April 19, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and s
Read more →RMTIRockwell Medical Data Safety Monitoring Board Recommends SFP Phase III Efficacy Studies to Continue as Planned
WIXOM, Mich., March 19, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and s
Read more →RMTIRockwell Medical Reports 2011 and Fourth Quarter Results
WIXOM, Mich., March 1, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and se
Read more →RMTISource: Rockwell Medical Technologies, Inc. Rockwell Medical Closes $17.5 million Registered Common Stock Offering WIXOM, MICHIGAN
Rockwell Medical Closes $17.5 million Registered Common Stock Offering WIXOM, MICHIGAN, February 15, 2012 Rockwell Medical (Nasdaq: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative pro
Read more →RMTIRockwell Medical Closes $17.5 million Registered Common Stock Offering
WIXOM, Mich., Feb. 15, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and se
Read more →RMTISource: Rockwell Medical Technologies, Inc. Rockwell Medical Prices Registered Common Stock Offering WIXOM, MICHIGAN
Rockwell Medical Prices Registered Common Stock Offering WIXOM, MICHIGAN, February 9, 2012 Rockwell Medical Technologies, Inc. (Nasdaq: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative
Read more →RMTIRockwell Medical Prices Registered Common Stock Offering
WIXOM, Mich., Feb. 9, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron
Read more →RMTIRockwell Medical Schedules Conference Call Reporting Fourth Quarter and Year End Results WIXOM, MICHIGAN
Rockwell Medical Schedules Conference Call Reporting Fourth Quarter and WIXOM, MICHIGAN, January 27, 2012 Rockwell Medical (Nasdaq: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative pro
Read more →RMTIRockwell Medical Schedules Conference Call Reporting Fourth Quarter and Year End Results
WIXOM, Mich., Jan. 27, 2012 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and se
Read more →RMTIRockwell Medical Data Safety Monitoring Board Recommends Phase III CRUISE Studies Continue as Planned
WIXOM, Mich., Dec. 12, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and se
Read more →RMTIRockwell Medical Reports Third Quarter 2011 Results
WIXOM, Mich., Nov. 3, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency and sec
Read more →RMTIRockwell Medical Schedules Conference Call
WIXOM, Mich., Oct. 28, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, announced toda
Read more →RMTIRockwell Medical to Present at JMP Securities Healthcare Conference
WIXOM, Mich., Sept. 21, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, announced to
Read more →RMTIRockwell Medical Appoints Annamaria T. Kausz, M.D., M.S. to VP of Drug Development and Medical Affairs
WIXOM, Mich., Sept. 19, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ERSD), chronic kidney disease (CKD), and iron deficiency anemia, announced to
Read more →RMTIRockwell Medical to Present at Wedbush Life Sciences Management Access Conference
WIXOM, Mich., Aug. 11, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, today announc
Read more →RMTIRockwell Medical Reports Second Quarter 2011 Results
WIXOM, Mich., Aug. 4, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, today announced
Read more →RMTIRockwell Medical Schedules Investor Conference Call
WIXOM, Mich., July 28, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, announced toda
Read more →RMTIRockwell Medical Announces Acquisition of Generic Drug Vitamin-D to Treat Secondary Hyperparathyroidism in ESRD Patients
WIXOM, Mich., July 26, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced tod
Read more →RMTIRockwell Medical Gains Membership Into the Russell 2000 Index
WIXOM, Mich., June 29, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, today announc
Read more →RMTIRockwell Medical Announces U.S. Patent Issued for SFP Packaging and Method of Use
WIXOM, Mich., May 11, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced toda
Read more →RMTIRockwell Medical Reports First Quarter 2011 Results
WIXOM, Mich., May 5, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, today announced
Read more →RMTIRockwell Medical Begins Second Phase III Clinical Trial for Treatment of Iron Deficiency in Dialysis Patients
WIXOM, Mich., April 26, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, announced to
Read more →RMTIRockwell Medical Appoints Dr. Alvin L. Crumbliss to Scientific Advisory Board
WIXOM, Mich., April 15, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, reported tod
Read more →RMTIRockwell Medical Announces New Supply Agreement With DaVita Inc.
WIXOM, Mich., March 28, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced to
Read more →RMTIRockwell Medical Starts Pivotal Phase III Clinical Study for Treatment of Iron Deficiency in Dialysis Patients
WIXOM, Mich., March 24, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, announced to
Read more →RMTIRockwell Medical Reports Fourth Quarter and Full Year 2010 Results
2010 Gross Profit up $2 Million; Net Loss Decreased $2.8 Million Conference call at 8:30am ET to discuss results WIXOM, Mich., March 3, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and service
Read more →RMTIRockwell Medical to Present at Citi 2011 Global Health Care Conference
WIXOM, Mich., Feb. 23, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, today announc
Read more →RMTIRockwell Medical Commences PRIME Clinical Study; ESA Sparing Examined in Hemodialysis Patients Receiving SFP-Iron
WIXOM, Mich., Feb. 16, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, announced tod
Read more →RMTIRockwell Medical Announces Largest Dialysis Organizations in U.S. to Participate in Phase III CRUISE Studies
WIXOM, Mich., Jan. 25, 2011 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced tod
Read more →RMTIRockwell Medical Presents New Data on Proprietary Iron-Delivery Drug SFP at American Society of Nephrology Annual Meeting
WIXOM, Mich., Nov. 19, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced tod
Read more →RMTIRockwell Medical to Present at the Annual Piper Jaffray Health Care Conference
WIXOM, Mich., Nov. 17, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, today announce
Read more →RMTIRockwell Medical to Present Data at American Society of Nephrology (ASN) Annual Meeting
WIXOM, Mich., Nov. 3, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced toda
Read more →RMTIRockwell Medical Announces SFP Patent Issuance for Its Proprietary GMP Formulation in the U.S.
WIXOM, Mich., Oct. 26, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced tod
Read more →RMTIRockwell Medical Announces Design of Phase III Iron Therapy Program for SFP
WIXOM, Mich., Oct. 20, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron-deficiency anemia, announced tod
Read more →RMTIRockwell Medical Appoints Carl Belczynski as VP of Investor Relations
WIXOM, Mich., Oct. 5, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, reported today
Read more →RMTIRockwell Medical to Present at the Fifth Annual JMP Securities Healthcare Conference
WIXOM, Mich., Sept. 13, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, today announ
Read more →RMTIRockwell Medical Appoints Dr. Iain Macdougall to Scientific Advisory Board
WIXOM, Mich., Aug. 16, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, reported toda
Read more →RMTIRockwell Medical Reports Record Second Quarter Results
- Revenues Increase 19.2 %; Gross Profit Increases 49% - - Conference Call at 8:30am ET to Discuss Results and Review Clinical Development - WIXOM, Mich., Aug. 5, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering inno
Read more →RMTIRockwell Medical Successfully Completes FDA Meeting Regarding SFP
WIXOM, Mich., July 8, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced toda
Read more →RMTIRockwell Medical to Present Phase IIb Data at XLVII ERA-EDTA Congress in Munich, Germany June 25-28, 2010
WIXOM, Mich., May 25, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced toda
Read more →RMTIRockwell Medical to Present at the Ninth Annual JMP Securities Research Conference
WIXOM, Mich., May 4, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, today announced
Read more →RMTIRockwell Collins Selects SPARK Pro for Security and Information Assurance
NEW YORK, NY and PARIS and SAN JOSE, CA--(Marketwire - April 27, 2010) - Embedded Systems Conference - AdaCore, a leading supplier of Ada development tools and support services, today announced the selection of SPARK Pro by Rockwell Collins for use on selected projects that have
Read more →RMTIRockwell Medical Appoints Dr. Ajay Singh to Scientific Advisory Board
WIXOM, Mich., April 15, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, reported tod
Read more →RMTIRockwell Medical Reports Excellent Fourth Quarter and Full Year 2009 Business Results
Gross Profit Increases $2.25 million in Q4; Gross Profit up 215% for the Year Conference Call at 4:15pm ET to Discuss Results and Review Clinical Development WIXOM, Mich., March 10, 2010 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq: RMTI), a fully-integrated biopharmaceutical c
Read more →RMTIRockwell Medical Announces Positive Phase IIb Clinical Data SFP Well-Tolerated; No Apparent Toxicity; Dosing for Phase III Program Determined; Conference Call
Rockwell Medical Announces Positive Phase IIb Clinical Data SFP Well-Tolerated; No Apparent Toxicity; Dosing for Phase III Program Determined; Conference Call February 26, 2010 at 8:30AM EST WIXOM, Mich., Feb. 25, 2010 Rockwell Medical (Nasdaq:RMTI), a fully-integrated bioph
Read more →RMTIRockwell Medical Reports Third Quarter Results; Expanded Gross Profit Margins
WIXOM, Mich., Nov. 4, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anemia, reported today
Read more →RMTIRockwell Medical Completes SFP Phase IIb Clinical Study
WIXOM, Mich., Oct. 29, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced tod
Read more →RMTIRockwell Medical Technologies, Inc. to Present Abstract At American Society of Nephrology (ASN) Annual Meeting
WIXOM, Mich., Oct. 13, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency an
Read more →RMTIRockwell Medical Technologies, Inc. Appoints Jur Strobos M.D. to Scientific Advisory Board
WIXOM, Mich., Oct. 6, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency ane
Read more →RMTIRockwell Medical Technologies, Inc. Announces Closing of $22 Million Registered Direct Offering of Shares and Warrants
WIXOM, Mich., Oct. 5, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ERSD), chronic kidney disease (CKD), and iron deficiency ane
Read more →RMTISource: Rockwell Medical Technologies, Inc. Rockwell Medical Technologies, Inc. Announces Closing of $22 Million Registered Direct Offering of Shares and Warrants Company secures capital needed for SFP clin
Rockwell Medical Technologies, Inc. Announces Closing of $22 Million Registered Direct Offering of Shares and Warrants Company secures capital needed for SFP clinical development WIXOM, MICHIGAN, October 5, 2009 Rockwell Medical Technologies, Inc. (Nasdaq: RMTI), a fully-inte
Read more →RMTIRockwell Medical Technologies to Present At the 2009 JMP Securities Healthcare Focus Conference
WIXOM, Mich., Oct. 1, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency anem
Read more →RMTICOMPANY PRESS RELEASE ROCKWELL MEDICAL TECHNOLOGIES, INC. ANNOUNCES $22 MILLION REGISTERED DIRECT OFFERING Wixom, Michigan
COMPANY PRESS RELEASE ROCKWELL MEDICAL TECHNOLOGIES, INC. ANNOUNCES $22 MILLION REGISTERED DIRECT OFFERING Wixom, Michigan, September 30, 2009 Rockwell Medical Technologies, Inc. (Nasdaq: RMTI) announced today that it has obtained commitments from institutional investors to pu
Read more →RMTIRockwell Medical Technologies, Inc. Announces $22 Million Registered Direct Offering
WIXOM, Mich., Sept. 30, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI) announced today that it has obtained commitments from institutional investors to purchase an aggregate of 2,840,000 shares of Rockwell's common stock and warrants to purchase up to
Read more →RMTIRockwell Medical Technologies, Inc. Reports Results for Second Quarter 2009
WIXOM, Mich., Aug. 10, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency ane
Read more →RMTIRockwell Medical Technologies, Inc. Schedules Investor Conference Call
WIXOM, Mich., Aug. 4, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI) announced today that it will hold an investor conference call on Monday, August 10, 2009 at 4:15 p.m. EDT to discuss its second quarter results and to provide investors with a busines
Read more →RMTIRockwell Medical Technologies, Inc. Appoints Ajay Gupta M.D. as Chief Scientific Officer
WIXOM, Mich., June 30, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency an
Read more →RMTIRockwell Medical Technologies Named to Russell Indexes
WIXOM, Mich., June 29, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD) and iron deficiency ane
Read more →RMTIRockwell Medical Technologies, Inc. Reports Results for First Quarter 2009
WIXOM, Mich., May 11, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ERSD), chronic kidney disease (CKD) and iron deficiency anem
Read more →RMTIRockwell Medical Technologies, Inc. Announces Patient Enrollment Complete for Phase 2b Dose Range Study
WIXOM, Mich., April 29, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ERSD), chronic kidney disease (CKD), and iron deficiency a
Read more →RMTIRockwell Medical Technologies, Inc. Announces Updated DSMB Interim Results; No Safety Issues Reported
WIXOM, Mich., April 16, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ERSD), chronic kidney disease (CKD), and iron deficiency a
Read more →RMTIRockwell Medical Technologies, Inc. Reports Fourth Quarter 2008 Results; Sales Increase 20% Year-Over-Year to $51.6 Million
WIXOM, Mich., March 16, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ERSD), chronic kidney disease (CKD), and iron deficiency a
Read more →RMTIRockwell Medical Technologies, Inc. Appoints Richard Yocum, M.D. as VP of Drug Development and Medical Affairs
WIXOM, Mich., March 2, 2009 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ERSD), chronic kidney disease (CKD), and iron deficiency an
Read more →RMTIRockwell Medical Technologies, Inc. Reports Third Quarter Results; Sales Gain of 22.2 Percent
WIXOM, Mich., Nov. 13, 2008 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), an innovative specialty pharma company developing renal drug therapies and manufacturing dialysate products, reported third quarter 2008 sales of $13.5 million, an increase of 22.2%
Read more →RMTIRockwell Medical Technologies to Present At the 2008 Rodman & Renshaw Annual Global Investment Conference
WIXOM, Mich., Nov. 6, 2008 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a specialty pharma company focused on drug and device development in the renal market, today announced that Robert Chioini, Chief Executive Officer, will present at the Rodman & Rens
Read more →RMTIRockwell Medical Technologies, Inc. Announces Updated DSMB Results; Identifies No Safety Concerns for SFP
WIXOM, Mich., Oct. 29, 2008 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a specialty pharma company focused on drug and device development in the renal market, reported today that the independent Data Safety Monitoring Board (DSMB) providing oversight fo
Read more →RMTIRockwell Medical Technologies to Present At the 2008 Oppenheimer 19th Annual Healthcare Conference
WIXOM, Mich., Oct. 27, 2008 (GLOBE NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a specialty pharma company focused on drug and device development in the renal market, today announced that Robert L. Chioini, Chief Executive Officer, will present at the Oppenheim
Read more →RMTIRockwell Medical Technologies, Inc. Reports Second Quarter Sales Increase of 15.5 Percent; Margins Increase Sequentially
WIXOM, Mich., Aug. 12, 2008 (PRIME NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), an innovative specialty pharma company developing renal drug therapies and essential dialysate products, reported second quarter 2008 sales of $12.2 million, an increase of 15.5% ov
Read more →RMTIRockwell Medical Technologies, Inc. Appoints Dr. Richard Hurrell, International Iron Expert, to Scientific Advisory Board
WIXOM, Mich., July 9, 2008 (PRIME NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a specialty pharma company focused on drug and device development in the renal market, reported today that it has added Dr. Richard Hurrell, an internationally recognized expert in t
Read more →RMTIRockwell Medical Technologies, Inc. Appoints Dr. James D. Cook to Scientific Advisory Board
WIXOM, Mich., June 17, 2008 (PRIME NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a specialty pharma company focused on drug and device development in the renal market, reported today that it has added Dr. James D. Cook, an internationally recognized expert in th
Read more →RMTIRockwell Medical Technologies, Inc. Appoints Dr. Richard Zager to Scientific Advisory Board
WIXOM, Mich., June 10, 2008 (PRIME NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a specialty pharma company focused on drug and device development in the renal market, reported today that it has added Dr. Richard Zager, an expert in acute renal injury and renal
Read more →RMTIRockwell Medical Technologies, Inc. to Present At 2008 Barrington Research Healthcare Conference
WIXOM, Mich., May 20, 2008 (PRIME NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI) today announced that Robert L. Chioini, President and CEO, and Thomas Klema, CFO of Rockwell Medical Technologies, Inc., will present an overview of the Company at the Barrington Rese
Read more →RMTIRockwell Medical Technologies, Inc. Reports First Quarter; Sales Increase 31 Percent; SFP Development Efforts
WIXOM, Mich., May 7, 2008 (PRIME NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products, reported record first quarter 2008 sales of $12.4 million, an increase of 31
Read more →RMTIRockwell Medical Technologies, Inc. Reports Fourth Quarter 2007 Results; Year-end Sales Increase 50 Percent
WIXOM, Mich., March 6, 2008 (PRIME NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products, reported record fourth quarter 2007 sales of $11.95 million, up 29.5% as c
Read more →RMTIRockwell Medical Technologies, Inc. Reports Patients Begin Dosing in NIH Funded SFP Clinical Study
WIXOM, Mich., Jan. 31, 2008 (PRIME NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI) a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products focused on the end-stage-renal-disease (ESRD) market, announced today that t
Read more →RMTIRockwell Medical Technologies, Inc. Announces Patient Enrollment Begins for NIH Funded SFP Clinical Study
WIXOM, Mich., Jan. 23, 2008 (PRIME NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI) a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products focused on the end-stage-renal-disease (ESRD) market, announced today that p
Read more →RMTIRockwell Medical Technologies, Inc. Reports FDA Approves Start of NIH Sponsored Study of Iron Therapy Drug, SFP
WIXOM, Mich., Dec. 4, 2007 (PRIME NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products, reported today that the FDA has approved initiation of a National Institute
Read more →RMTIRockwell Medical Technologies, Inc. Closes $12.95 Million Financing
WIXOM, Mich., Nov. 29, 2007 (PRIME NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products, announced today that it has raised $12,950,000 in gross proceeds from a pr
Read more →RMTIRockwell Medical Technologies, Inc. Reports Third Quarter Results; Sales Increase 50 Percent
WIXOM, Mich., Nov. 8, 2007 (PRIME NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products, reported record quarterly sales of $11.1 million for the third quarter of 2
Read more →RMTIRockwell Medical Technologies, Inc. Receives Patent Grant for Proprietary SFP Iron-Delivery in Mexico
WIXOM, Mich., Oct. 23, 2007 (PRIME NEWSWIRE) -- Rockwell Medical Technologies, Inc. (Nasdaq:RMTI), a leading, innovative manufacturer and developer of renal drug therapies and essential dialysate products, focused on the end-stage-renal-disease (ESRD) market, reported that a Mexi
Read more →Competitive Position
How RMTI ranks across every disease it competes inCompetitive Position is a premium feature
See how RMTI ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial